| Budget Amount *help |
¥1,900,000 (Direct Cost: ¥1,900,000)
Fiscal Year 1997: ¥400,000 (Direct Cost: ¥400,000)
Fiscal Year 1996: ¥1,500,000 (Direct Cost: ¥1,500,000)
|
|---|
| Research Abstract |
The pharmacokinetics, biological effects and distribution in blood and organs of <@D1125@>D1I-labeled (1*3)-beta-D-glucan purified from Candida albicans were analyzed in rabbits during the 24 hr period following its I.V.administration. The intravascular half-life (T<@D21/2@>D2alpha) of beta-glucan was 1.8 min in the low dose group (9.3mug/kg) and 1.4 min in the high dose group (222mug/kg), and the total body clearance was 1.12 (]SY.+-。[) 0.30 and 1.17 (]SY.+-。[) 0.16 (ml/min, mean (]SY.+-。[) SD), respectively. The serum concentration of (1*3)-beta-D-glucan was also biologically determined by a test using coagulation factor G of the Japanese horseshoe crab (G Test). There was a good correlation between the concentration of beta-glucan, measured biologically and isotopically, during the initial 2 hr period ; however, biological activity then decreased faster than the isotopic concentration of beta-glucan during the 3-24 hr period. During the 24 hr period of observation, the rabbits remained well and beta-glucan failed to alter blood cell counts, TNF levels, and lipid metabolism. <@D1125@>D1I-beta-glucan associated with the cellular compartment initially was less than 3% (the majority in the platelets), and decreased further during the following 2 hr period (p=0.0001). Over 97% of <@D1125@>D1I-beta-glucan was associated with the cell-free plasma and the majority in plasma appeared to be present in unbound form, i.e., not associated with lipoproteins or plasma proteins. The liver contained more than 80% of the <@D1125@>D1I-beta-glucan detected in the six major organs analyzed.
|
